A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer

Inclusion Criteria: * histologically or cytologically confirmed extensive disease of Small cell lung cancer * no prior chemotherapy or radiotherapy for lung * measurable lesion for RECIST * over 18 years * ECOG 0\~2 * expected life span more than 3 months Exclusion Criteria: * acute or active infection * uncontrolled cerebral nerve symptoms or metastasis * significant myocardial infarction or cardiac disease within 12 months